UK allows pre-implantation tissue typing
This article was originally published in Clinica
Executive Summary
The Human Fertilisation and Embryology Authority (HFEA) has decided, "in principle", to allow tissue typing to be used in conjunction with preimplantation genetic diagnosis (PGD) for "severe genetic disease". The decision enables the selection of embryos that are not only free from a specific congenital disease but in which the blood from its umbilical cord might be used in the treatment of a sibling affected by the disease.
You may also be interested in...
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.